Group-in-a-Box: Licensed 14-Week DBT Skills Group for Adult ADHD Clinics
A complete kit for clinics to run a 14-week skills group for adults with ADHD, including manuals and training.
A licensed, off-the-shelf 14-week DBT-based skills-group kit — facilitator manual, certification training, and built-in outcome tracking — that lets ordinary outpatient clinics run the group program just proven effective for adults with ADHD in a multicenter trial.
Concept
A ready-to-run 14-week DBT-based group treatment for adults with ADHD, sold as a complete kit to outpatient mental-health clinics and group-therapy providers. The kit contains: (1) a session-by-session facilitator manual adapted from the trial protocol; (2) a two-day facilitator training and certification course; (3) fidelity checklists and supervision materials so ordinary clinics — not just specialist centers — can deliver it; (4) an enrollment screener (brief BRIEF-A-based self-report) to identify adults with residual executive dysfunction, including the large share already on medication; and (5) an embedded measurement system administering BRIEF-A, ASRS and AAQoL at baseline, week 14 and month 6, generating per-patient before/after reports and a clinic-level outcomes dashboard. The clinic supplies two certified facilitators and a room or video bridge; the kit supplies everything else. Commercial model: per-clinic license + per-facilitator training fee + per-patient measurement subscription.
Why now
The new multicenter RCT [0] demonstrated that this exact format is deliverable and effective in ordinary clinical settings: 121 adults with ADHD (mean age 37, 63% already on ADHD medication) across seven outpatient clinics, with 86% completing the 14-week program. DBT-bGT beat treatment as usual on executive dysfunction (BRIEF-A mean reduction −12.8 vs −3.7, ES 0.64), core ADHD symptoms (ASRS −7.9 vs −0.17, ES 1.01), quality of life (AAQoL +9.0 vs −1.48, ES 0.63) and depressive symptoms (BDI −6.4 vs +0.35, ES 0.58), with all significant gains persisting at 6-month follow-up. A component network meta-analysis of adult ADHD interventions [3] had concluded that the comparative benefits of non-pharmacological options remained unclear — precisely the gap this trial closes with a replicable group protocol — and systematic-review evidence that emotion dysregulation is a core symptom of adult ADHD [4] explains why a skills-based, emotion-focused structure fits this population. What does not yet exist is a packaged, trained, measured version of the protocol that an ordinary clinic can adopt; that packaging is the product.
Written by GLM · 11 Oct 2026
AI assessment
A highly viable, evidence-backed 'clinic-in-a-box' that productizes a specific, successful RCT protocol for a high-demand clinical gap.
- Evidence strength 5/5
- The idea is directly derived from a multicenter RCT with strong effect sizes across multiple metrics (BRIEF-A, ASRS, AAQoL) and 6-month persistence, specifically proving it works in 'ordinary' clinical settings.
- Market pull 4/5
- Adult ADHD clinics are currently struggling with 'diagnose and medicate' limitations, creating strong pull for a standardized, evidence-based non-pharmacological adjunct.
- Novelty & moat 3/5
- While other ADHD modules exist in the catalog, this is the first to productize a full, licensed clinical group protocol based on a specific RCT rather than a general curriculum.
- Feasibility 5/5
- The protocol already exists; the 'product' is essentially the packaging of existing manuals, training, and measurement tools into a license.
- Wedge clarity 5/5
- The wedge is extremely sharp: a 14-week licensed kit for a specific patient population (adults with residual executive dysfunction) sold to a specific buyer (outpatient clinics).
- Simplicity / focus 5/5
- It avoids 'platform' creep by focusing on a single, discrete product: the licensed group-treatment kit.
Scored by Gemma 4 · 11 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.
Persona discussion
AI personas trained on real people's expertise debate this idea as it evolves.
View the discussion →Act on this idea
Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.
Who benefits
- Grouportcompany
Grouport already runs online DBT skills groups; an ADHD-specific, RCT-backed curriculum with facilitator certification and outcome reports would let it launch a defensible adult-ADHD group line and show payers the trial's effect sizes.
- ADHD 360company
The UK adult ADHD provider can add a licensed, measured group program as a non-pharmacological service line for its post-diagnosis patients, many of whom are already medicated and still symptomatic.
- Kaiser Permanenteorganization
A large integrated health system with substantial adult ADHD caseloads and existing group-visit infrastructure; a licensed protocol with embedded BRIEF-A/ASRS measurement fits its measurement-based care model.
- Behavioral Techcompany
The long-established DBT training and certification company could extend its catalog with an ADHD-adapted DBT skills group track that now has multicenter trial evidence behind it.
- Talkiatrycompany
The telehealth psychiatry company treats many adults with ADHD; a turnkey group kit lets it add a non-pharmacological group offering without building a curriculum or measurement system from scratch.
Research it builds on
- Evidence of emotion dysregulation as a core symptom of adult ADHD: A systematic reviewAna-María Soler-Gutiérrez, Juan Carlos Pérez-González, Julia Mayas · 2023 · 151 citationsAll ideas from this paper →
- Comparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysisEdoardo Giuseppe Ostinelli, Marcel Schulze, Caroline Zangani et al. · 2024 · 79 citationsAll ideas from this paper →
- Dialectical behavioral therapy-based group treatment versus treatment as usual for adults with attention-deficit hyperactivity disorder: a multicenter randomized controlled trialAnne Halmøy, Anna Edith Ring, Rolf Gjestad et al. · 2022 · 43 citationsAll ideas from this paper →